Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Subscribe To Our Newsletter & Stay Updated
